Exosome Diagnostics, Qiagen Seek to Move Biofluid Nucleic Acid Sample Prep to Research Community | GenomeWeb

This article has been updated from a previous to clarify language about Exosome's technology.

Exosome Diagnostics and Qiagen this week announced a partnership to develop and commercialize co-branded kits to capture and process RNA and DNA from biofluid exosomes and other microvesicles.

New York-based Exosome is betting that the agreement, which will initially focus on microRNA isolation, will enable the company to disseminate its proprietary exosome technology to the research community for biomarker discovery applications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.